News from daiichi sankyo company, limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Nov 05, 2018, 02:00 ET EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the European Medicines Agency (EMA) validated for review and granted...


Nov 01, 2018, 09:15 ET Daiichi Sankyo to Present Data from AML Franchise Including FLT3 Inhibitor Quizartinib at ASH Annual Meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it will present data on investigational compounds in the AML Franchise...


Oct 21, 2018, 06:45 ET Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab...


Oct 18, 2018, 08:00 ET Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a first-in-human phase 1 study...


Oct 17, 2018, 08:00 ET Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has submitted a New Drug Application (NDA) to Japan's Ministry of...


Oct 03, 2018, 10:00 ET Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that axicabtagene ciloleucel (formerly KTE-C19) has been granted Orphan...


Sep 25, 2018, 08:00 ET Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Positive Metastatic Breast Cancer including Head-to-Head Versus T-DM1 and Post-T-DM1 Study

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patients have been dosed in DESTINY-Breast03 and...


Sep 24, 2018, 10:30 ET Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab deruxtecan ...


Sep 20, 2018, 08:00 ET Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with a...


Sep 11, 2018, 08:00 ET Daiichi Sankyo's FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that quizartinib, an investigational FLT3 inhibitor, has been granted Orphan...


Aug 28, 2018, 03:00 ET Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA®▼ (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice

The Global ETNA-AF programme is a large and comprehensive single non-vitamin K oral anticoagulant (NOAC) repository of real-world data, as part of...


Aug 13, 2018, 06:02 ET New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®▼ (edoxaban)

Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent...


Aug 01, 2018, 08:00 ET FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...


Jul 30, 2018, 08:00 ET Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive worldwide...


Jun 18, 2018, 06:51 ET Phase-III-Studie QuANTUM-R belegt, dass Quizartinib von Daiichi Sankyo als Einzelwirkstoff das Gesamtüberleben bei Patienten mit rezidivierter/refraktärer AML mit FLT3-ITD Mutationen im Vergleich zu Chemotherapie verlängert

-- Daten aus QuANTUM-R, vorgestellt als Late-Breaking-Vortrag im Rahmen einer Plenarsitzung anlässlich des 23. Kongresses der European Hematology...


Jun 16, 2018, 08:30 ET Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo's Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that positive results from the pivotal QuANTUM-R phase 3 study of single agent...


Jun 06, 2018, 08:00 ET Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that topline results from the pivotal QuANTUM-R phase 3 study of single...


Jun 01, 2018, 08:00 ET Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that long-term phase 1 safety and efficacy data for DS-8201, an investigational ...


Jun 01, 2018, 08:00 ET Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that preliminary data from the dose escalation part of an ongoing phase 1/2...


May 31, 2018, 08:00 ET Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been dosed in a global phase 2 study...


May 16, 2018, 05:05 ET Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new data for multiple investigational compounds in...


May 08, 2018, 03:00 ET Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib met its...


Mar 27, 2018, 10:00 ET Daiichi Sankyo's HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that DS-8201, an investigational HER2-targeting antibody drug conjugate...